Spruce Biosciences, Inc. expected to post a loss of $5.80 a share - Earnings Preview

Spruce Biosciences

10/08/2026 12:12

Spruce Biosciences, Inc. SPRB.OQ SPRB.O is expected to  show no change in quarterly revenue when it reports  results on August 12 (estimated) for the period ending June 30 2026

​LSEG's mean analyst estimate for Spruce Biosciences, Inc. is for a loss of $5.80 per share. 
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 8 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."  
The mean earnings estimate of analysts was unchanged in the last three months. ​
Wall Street's median 12-month price target for Spruce Biosciences, Inc. is $145.00, about 209.4% above its last closing price of $46.87
Previous quarterly performance (using preferred earnings measure in US dollars). ​
QUARTER ENDING
STARMINESMARTESTIMATE®
LSEG IBES ESTIMATE 
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Mar. 31 2026
-8.54
-8.82
-8.94
Missed
-1.4
Dec. 31 2026
-12.00
-7.99
-11.28
Missed
-41.3
Sep. 30 2025
-13.32
-13.93
-14.58
Missed
-4.6​
Jun. 30 2025
-18.00
-19.12
-3.50
Beat
81.7
​​Mar. 31 2025
-17.71
-16.09
-24.00
Missed
-49.1
Dec. 31 2024
-14.25
-15.75
-42.75
Missed
-171.4​
Sep. 30 2024
-17.30
-17.81
-15.75
Beat
11.6
Jun. 30 2024
-24.05
-24.06
-16.50
Beat
31.4
This summary was machine generated August 10 at 11:12 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)